Graph Therapeutics develops an AI-powered platform to bring the precision medicine paradigm to inflammation and immunology (I&I) drug discovery.
Their platform combines complex primary disease models with advanced machine learning to bridge the gap between pre-clinical models and clinical applications. “The complexity of inflammatory and immunological diseases demands a fundamentally different approach to drug discovery. Graph Therapeutics represents what we see as ‘Techbio 3.0’,” explains Dr. Gregory Vladimer, CEO and co-founder of Graph Therapeutics.
"I’m greatly appreciative of BRANDL TALOS’s expert and reliable support in organizing this financing round. I look forward to many further projects with them as we build Graph", says Dr. Gregory Vladimer, CEO and co-founder of Graph Therapeutics
BRANDL TALOS consisted of Stephan Strass and Lara Präthaler. Squareone was advised by Schönherr (Thomas Kulnigg and Clemens Pretscher), NAVEC was represented by Herbst Kinsky (Philipp Kinsky) and the Atomico Angel Program was advised by Fladgate (Ellie Green).